An interim analysis of NATALEE, a phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence demonstrated positive topline results.
Results of a multi-institutional clinical trial recently published in the Journal of Clinical Oncology show that surgically removing affected lymph nodes in the retroperitoneum of patients with early metastatic seminoma is an effective alternative to chemotherapy and radiation, with fewer long-term side effects.
A study published in Blood Advances demonstrates that patients with blood cancers experienced a significant improvement in their reported well-being six months after receiving CAR T-cell therapy.
By investigating non-antibiotic-disrupted microbiomes, MD Anderson Cancer Center researchers developed a machine-learning algorithm that can predict long-term response to CAR T therapy using microbiome-based biomarkers. The study was published in Nature Medicine.
The breast tumors of Asian, Black and white patients have very different cellular, microbial, and genomic features that could potentially be used to personalize care or predict disease progression, according to research by investigators at the Johns Hopkins Kimmel Cancer Center.
Researchers at the University of Cincinnati developed an approach to radionuclide therapy which uses engineered bacteria to target cancer cells without endogenously targetable receptors.
MD Anderson researchers, led by Renata Ferrarotto, conducted a phase II trial evaluating the combination of the VEGFR inhibitor axitinib plus the PD-L1 inhibitor avelumab in 28 patients with progressive recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer for which there are limited treatment options.
A novel approach to administer intrathecal immunotherapy (directly into the spinal fluid) and intravenous immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease from metastatic melanoma, according to interim analyses of a phase I/Ib trial led by researchers at MD Anderson Cancer Center.
Cancer and its treatment can accelerate the rate of aging because they both destabilize and damage biological systems in the body. Research published in Cancer, a journal of the American Cancer Society, found that African American cancer survivors who reported high levels of discrimination exhibited greater aging and frailty than those reporting lower levels of discrimination.
Investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that treatment outcomes for patients with malignant pleural mesothelioma, a rare cancer commonly known as mesothelioma, are often affected by social determinants of health and that overall survival rates could be improved by addressing these health disparities and improving access to specialized care.
